Literature DB >> 8849252

Analysis of phosphorylation pathways of antiherpesvirus nucleosides by varicella-zoster virus-specific enzymes.

S Koyano1, T Suzutani, I Yoshida, M Azuma.   

Abstract

The inhibitory activities of acyclovir (ACV), 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU), ganciclovir (GCV), 9-(2-deoxy-2-hydroxymethyl-beta-D-erythro-oxetanosyl)guanine (OXT-G), and (+)-9-[(1R,2R,3S)-2,3-bis(hydroxymethyl)Cyclobutyl]guanine (cOXT-G) on the replication of wild-type and thymidine kinase (TK)-negative strains of herpes simplex virus types 1 and 2 and varicella-zoster virus (VZV) and the wild-type strain of human cytomegalovirus were tested to clarity whether the phosphorylation of these compounds is catalyzed by viral TK or other enzymes. ACV and BV-araU had little effect on the replication of TK-negative virus strains. On the other hand, GCV, OXT-G, and cOXT-G inhibited the replication of TK-negative VZV at concentrations 10 times higher than those at which they inhibited wild-type VZV, indicating that a kinase other than TK phosphorylates GCV and OXT-G in VZV-infected cells. GCV phosphorylation activity was not detected in VZV-infected cell lysates; therefore, this activity was evaluated in COS 1 cells expressing viral TK and viral protein kinase (PK). The COS 1 cells expressing VZV TK were shown to be susceptible to all compounds tested. In contrast, VZV Pk-expressing COS 1 cells were susceptible to only GCV, OXT-G, and cOXT-G. These results suggest that VZV PK phosphorylates some nucleoside analogs, for example, GCV, OXT-G, and cOXT-G. This phosphorylation pathway may be important in the anti-VZV activities of some nucleoside analogs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8849252      PMCID: PMC163231     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine.

Authors:  G B Elion; P A Furman; J A Fyfe; P de Miranda; L Beauchamp; H J Schaeffer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

2.  Double stranded DNA sequencing as a choice for DNA sequencing.

Authors:  H Zhang; R Scholl; J Browse; C Somerville
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

3.  Isolation and characterisation of resistant Herpes simplex virus after acyclovir therapy.

Authors:  W H Burns; R Saral; G W Santos; O L Laskin; P S Lietman; C McLaren; D W Barry
Journal:  Lancet       Date:  1982-02-20       Impact factor: 79.321

4.  Strains of varicella-zoster virus resistant to 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.

Authors:  T Sakuma
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

5.  In vitro susceptibility of varicella-zoster virus to acyclovir.

Authors:  K K Biron; G B Elion
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

6.  Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir.

Authors:  J C Wade; C McLaren; J D Meyers
Journal:  J Infect Dis       Date:  1983-12       Impact factor: 5.226

7.  Cell-free varicella-zoster virus in cultured human melanoma cells.

Authors:  C Grose; D M Perrotta; P A Brunell; G C Smith
Journal:  J Gen Virol       Date:  1979-04       Impact factor: 3.891

8.  Analysis of the relationship between cellular thymidine kinase activity and virulence of thymidine kinase-negative herpes simplex virus types 1 and 2.

Authors:  T Suzutani; S Koyano; M Takada; I Yoshida; M Azuma
Journal:  Microbiol Immunol       Date:  1995       Impact factor: 1.955

9.  Cytoplasmic 5'-nucleotidase catalyzes acyclovir phosphorylation.

Authors:  P M Keller; S A McKee; J A Fyfe
Journal:  J Biol Chem       Date:  1985-07-25       Impact factor: 5.157

10.  Unique spectrum of activity of 9-[(1,3-dihydroxy-2-propoxy)methyl]-guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1.

Authors:  Y C Cheng; E S Huang; J C Lin; E C Mar; J S Pagano; G E Dutschman; S P Grill
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

View more
  6 in total

Review 1.  Current recommendations for the treatment of genital herpes.

Authors:  D T Leung; S L Sacks
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

2.  In vitro-selected drug-resistant varicella-zoster virus mutants in the thymidine kinase and DNA polymerase genes yield novel phenotype-genotype associations and highlight differences between antiherpesvirus drugs.

Authors:  G Andrei; D Topalis; P Fiten; C McGuigan; J Balzarini; G Opdenakker; R Snoeck
Journal:  J Virol       Date:  2011-12-21       Impact factor: 5.103

3.  The UL97 gene product of human cytomegalovirus is an early-late protein with a nuclear localization but is not a nucleoside kinase.

Authors:  D Michel; I Pavić; A Zimmermann; E Haupt; K Wunderlich; M Heuschmid; T Mertens
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

4.  Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymerase.

Authors:  D J Tenney; G Yamanaka; S M Voss; C W Cianci; A V Tuomari; A K Sheaffer; M Alam; R J Colonno
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

5.  The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase.

Authors:  E A Gustafson; A C Chillemi; D R Sage; J D Fingeroth
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

Review 6.  Conserved herpesvirus protein kinases.

Authors:  Edward Gershburg; Joseph S Pagano
Journal:  Biochim Biophys Acta       Date:  2007-08-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.